InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,354.03
(
1.18%
)
US TECH 100
18,555.60
(
2.10%
)
Dow Jones
38,807.33
(
0.25%
)
Brent Oil
78.66
(
0.12%
)
Bitcoin
71,126.48
(
0.07%
)
Post# of 252072
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

RioLobo

Send PM Follow Ignore
Followers 0
Posts 29
Boards Moderated 0
Alias Born 07/23/2008

RioLobo

Re: None

Monday, 12/11/2017 2:07:15 PM

Monday, December 11, 2017 2:07:15 PM

Post# of 252072
Re: MNTA 281

argenx reports positive topline results from Phase 2 proof-of-concept trial of ARGX-113 (efgartigimod) in generalized myasthenia gravis

December 11, 2017

Favorable tolerability profile consistent with Phase 1 data
ARGX-113 treatment resulted in a strong clinical improvement over placebo during the entire duration of the study
75% of ARGX-113 treated patients had a clinically meaningful and statistically significant improvement through at least 6 consecutive study weeks versus 25% of patients on placebo
Management to host conference call today at 8:00 am EST
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up